Gilead Sciences, Inc. (LON:0QYQ)

Market Cap	139.22B +40.3%
Revenue (ttm)	21.88B +2.4%
Net Income	6.32B +1,672.9%
EPS	5.04 +1,684.2%
Shares Out	n/a
PE Ratio	22.02
Forward PE	17.32
Dividend	2.36 (1.56%)
Ex-Dividend Date	Dec 15, 2025

Volume	1,497
Average Volume	28,438
Open	152.60
Previous Close	152.93
Day's Range	150.46 - 154.00
52-Week Range	93.63 - 157.79
Beta	0.39
RSI	63.75
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QYQ

Financial Performance

In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.

Financial numbers in USD